ARTICLE | Politics, Policy & Law
Congressional spotlight on McKinsey over COI could reach pharmas
Documents raise questions about McKinsey’s work for FDA, life sciences clients
April 15, 2022 8:08 PM UTC
An investigation of McKinsey by a House committee is certain to cause government agencies, especially FDA, to reconsider their reliance on the firm. So far, the investigation has focused on FDA and manufacturers of opioids, but members of Congress are pushing McKinsey to provide information about its work for other companies.
Documents released by the committee provide glimpses of McKinsey & Co. business practices that might also raise questions among its private sector clients...